Issue 68

PSYCH Symposium: London 2022 – Europe’s premier psychedelic medicine conference

PSYCH Symposium: London 2022 will take place at the prestigious National Gallery on Wednesday, 11 May – unlocking the potential of psychedelic healthcare.

Connect with key decision makers, learn from industry leaders and share ideas and opportunities that will contribute to the future of psychedelic healthcare. As the industry expands, research briefings, regulatory updates and and topical debates will provide the intelligence and insights to navigate the emerging ecosystem.

‘I’m excited to join the PSYCH Symposium in May,’ said Doblin. ‘The UK and Europe have been making pioneering contributions to research on psychedelics. This conference will assist in the effort to provide access to and acceptance of psychedelics for clinical use in Europe.’

OREGON RELEASES DRAFT RULES FOR PSILOCYBIN FRAMEWORK

In the state’s psilocybin market, over 21s will be able to access the psychedelic medicine without diagnosis.

MINDSTATE DESIGN LABS RAISES US$11.5M IN SEED ROUND

The company plans to use the financing to develop a platform that designs altered states of consciousness.

BUSINESS AND INVESTMENT

Field Trip reports 2022 financial results.

Cybin provides Q3 2022 financial results.

Irwin Naturals to acquire ketamine clinics.

Core One acquires Awakened Biosciences.

Fluence raises US$3m for its education platform.

Inside Mindset Pharma’s deal with Otsuka.

VC money keeps flowing into psychedelics-based mental health.

SCIENCE AND RESEARCH

Ketamine for suicidal ideation.

Psychedelics and the future of psychiatry.

Are psychedelics dangerous? What the research says.

Can MDMA save a marriage?

Can microdosing psychedelics boost mental health?

Microdosing zebrafish with LSD shows its potential benefits for humans.

Are psychedelics the future of pain relief?

The Psychedelics as Medicine Report: Third Edition

The 200+ page Psychedelics as Medicine Report: Third Edition is the most comprehensive analysis of the psychedelic healthcare industry, empowering investors, operators and regulators to make informed decisions.

Key findings:

The medical psychedelic market is valued at US$190 million, and is expected to exceed US$2.4 billion by 2026.
Investment in psychedelic companies has now surpassed US$2 billion.
Two-thirds of North Americans and Europeans support the legalisation of psychedelic-assisted therapy.

Download your complimentary copy

VISIT ATAI LIFE SCIENCES' WEBSITE

REGULATION AND LEGISLATION

Health Canada denies dozens of requests to access psilocybin.

Bill to legalise psilocybin-assisted therapy fails in Maine.

Utah lawmakers vote to study benefits of psychedelic medicines.

Seattle doctor files DEA petition to reschedule psilocybin.

Advocates in Michigan file ballot initiative to decriminalise entheogens.

DEA faces backlash over proposed scheduling of tryptamines.

Experts in Washington say psilocybin can be a pathway to treatment.